Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), announced the appointment of Sara Kenkare-Mitra, PhD to the Company’s Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara’s leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive’s future growth.

American Resources Corp. (Nasdaq: AREC), a leading provider of next generation infrastructure inputs, announced that its Board of Directors has appointed Josh Hawes as an independent director. Hawes brings over 20 years of experience in the areas of capital market construction, organizational and product strategy and driving shareholder returns. Hawes will replace Michael Layman as an independent director of the board as well as a member of the Board's Audit Committee effective immediately. Layman will continue to advise the Company as a member of its Advisory Board.

BioVie (Nasdaq: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, hosted a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer’s Disease. The event focused on BioVie’s lead product candidate, NE3107, currently in a potentially pivotal Phase 3 study in patients with mild to moderate Alzheimer’s disease with expected topline data readout in the fourth quarter of 2023.

Genius Group (NYSE American: GNS), a leading entrepreneur edtech and education group, has launched Genius Metaversity 2.0, a virtual reality learning environment in partnership with GeniusX and Vatom Labs to hold educational courses and summits in the Metaverse.